Acute toxicity and its dosimetric correlates for high-risk prostate cancer treated with moderately hypofractionated radiotherapy

Abstract Aims To report the acute toxicity and the dosimetric correlates after moderately hypofractionated radiotherapy for localized prostate cancer. Methods A total of 101 patients with localized prostate cancer were treated with image-guided intensity-modulated radiation therapy. Patients were tr...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Medical dosimetry : official journal of the American Association of Medical Dosimetrists 2017, Vol.42 (1), p.18-23
Hauptverfasser: Arunsingh, Moses, M.D, Mallick, Indranil, M.D., D.N.B, Prasath, Sriram, M.Sc, Arun, B., M.Sc, Sarkar, Sandip, M.D, Shrimali, Raj Kumar, F.R.C.R, Chatterjee, Sanjoy, F.R.C.R, Achari, Rimpa, M.D
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 23
container_issue 1
container_start_page 18
container_title Medical dosimetry : official journal of the American Association of Medical Dosimetrists
container_volume 42
creator Arunsingh, Moses, M.D
Mallick, Indranil, M.D., D.N.B
Prasath, Sriram, M.Sc
Arun, B., M.Sc
Sarkar, Sandip, M.D
Shrimali, Raj Kumar, F.R.C.R
Chatterjee, Sanjoy, F.R.C.R
Achari, Rimpa, M.D
description Abstract Aims To report the acute toxicity and the dosimetric correlates after moderately hypofractionated radiotherapy for localized prostate cancer. Methods A total of 101 patients with localized prostate cancer were treated with image-guided intensity-modulated radiation therapy. Patients were treated to 65 Gy/25 Fr/5 weeks ( n = 18), or 60 Gy/20 Fr/4 weeks ( n = 83). Most (82.2%) had high-risk or pelvic node-positive disease. Acute toxicity was assessed using Radiation Therapy Oncology Group (RTOG) acute morbidity scoring criteria. Dose thresholds for acute rectal and bladder toxicity were identified. Results The incidence of acute grade 2 GI toxicity was 20.8%, and grade 2 genitourinary (GU) toxicity was 6.9%. No Grade 3 to 4 toxicity occurred. Small bowel toxicity was uncommon (Gr 2 = 4%). The 2 Gy equivalent doses (EQD2) to the rectum and bladder (α/β = 3) calculated showed that the absolute doses were more consistent predictors of acute toxicities than the relative volumes. Those with grade 2 or more GI symptoms had significantly higher V EQD2-60 Gy (13.2 vs 9.9 cc, p = 0.007) and V EQD2-50 Gy (20.6 vs 15.4 cc, p = 0.005). Those with grade 2 or more GU symptoms had significantly higher V EQD2-70 Gy (30.4 vs 18.4 cc, p = 0.001) and V EQD2-65 Gy (44.0 vs 28.8 cc, p = 0.001). The optimal cutoff value for predicting grade 2 acute proctitis, for V EQD2-60 Gy was 9.7 cc and for V EQD2-50 Gy was 15.9 cc. For grade 2 GU symptoms, the threshold values were 23.6 cc for V EQD2-70 Gy and 38.1 cc for V EQD2-65 Gy. Conclusions Hypofractionated radiotherapy for prostate cancer is well tolerated and associated with manageable acute side effects. The absolute dose-volume parameters of rectum and bladder predict for acute toxicities.
doi_str_mv 10.1016/j.meddos.2016.10.002
format Article
fullrecord <record><control><sourceid>pubmed_osti_</sourceid><recordid>TN_cdi_osti_scitechconnect_22685176</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0958394716300966</els_id><sourcerecordid>28129973</sourcerecordid><originalsourceid>FETCH-LOGICAL-c445t-e30a359d629834a0527ba4ba4150a2f985c6722bd94ee53bf0dcd1c707f9ea483</originalsourceid><addsrcrecordid>eNqFkUuLFDEQx4Mo7rj6DUQCnnusPPqRi7AsqysseFDPIZNU25nt6TRJxrVvfnTTtnrwIgRCVf3r9StCXjLYM2DNm-P-hM6FtOfFKq49AH9EdqxrRSWB88dkB6ruKqFke0GepXQEgFqCeEoueMe4Uq3YkR9X9pyR5vDdW58XaiZHfU60FPYnzNFbakOMOJqMifYh0sF_Haro0z2dY0i5-Kk1k8VIc8RiOfrg80BPwWEs5rjQYZlDH43NPky_BNE4H_JQ4vPynDzpzZjwxe__knx5d_P5-ra6-_j-w_XVXWWlrHOFAoyolWu46oQ0UPP2YGR5rAbDe9XVtmk5PzglEWtx6MFZx2wLba_QyE5cktdb3TKz16ksi3awYZrQZs1509WsbYpKbipbdksRez1HfzJx0Qz0il0f9YZdr9hXb8Fe0l5tafP5UMJ_k_5wLoK3mwDLit88xnUCLNScj-sALvj_dfi3gB395K0Z73HBdAznOBV8munENehP6-nXy7NGAKimET8BEHGtng</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Acute toxicity and its dosimetric correlates for high-risk prostate cancer treated with moderately hypofractionated radiotherapy</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Arunsingh, Moses, M.D ; Mallick, Indranil, M.D., D.N.B ; Prasath, Sriram, M.Sc ; Arun, B., M.Sc ; Sarkar, Sandip, M.D ; Shrimali, Raj Kumar, F.R.C.R ; Chatterjee, Sanjoy, F.R.C.R ; Achari, Rimpa, M.D</creator><creatorcontrib>Arunsingh, Moses, M.D ; Mallick, Indranil, M.D., D.N.B ; Prasath, Sriram, M.Sc ; Arun, B., M.Sc ; Sarkar, Sandip, M.D ; Shrimali, Raj Kumar, F.R.C.R ; Chatterjee, Sanjoy, F.R.C.R ; Achari, Rimpa, M.D</creatorcontrib><description>Abstract Aims To report the acute toxicity and the dosimetric correlates after moderately hypofractionated radiotherapy for localized prostate cancer. Methods A total of 101 patients with localized prostate cancer were treated with image-guided intensity-modulated radiation therapy. Patients were treated to 65 Gy/25 Fr/5 weeks ( n = 18), or 60 Gy/20 Fr/4 weeks ( n = 83). Most (82.2%) had high-risk or pelvic node-positive disease. Acute toxicity was assessed using Radiation Therapy Oncology Group (RTOG) acute morbidity scoring criteria. Dose thresholds for acute rectal and bladder toxicity were identified. Results The incidence of acute grade 2 GI toxicity was 20.8%, and grade 2 genitourinary (GU) toxicity was 6.9%. No Grade 3 to 4 toxicity occurred. Small bowel toxicity was uncommon (Gr 2 = 4%). The 2 Gy equivalent doses (EQD2) to the rectum and bladder (α/β = 3) calculated showed that the absolute doses were more consistent predictors of acute toxicities than the relative volumes. Those with grade 2 or more GI symptoms had significantly higher V EQD2-60 Gy (13.2 vs 9.9 cc, p = 0.007) and V EQD2-50 Gy (20.6 vs 15.4 cc, p = 0.005). Those with grade 2 or more GU symptoms had significantly higher V EQD2-70 Gy (30.4 vs 18.4 cc, p = 0.001) and V EQD2-65 Gy (44.0 vs 28.8 cc, p = 0.001). The optimal cutoff value for predicting grade 2 acute proctitis, for V EQD2-60 Gy was 9.7 cc and for V EQD2-50 Gy was 15.9 cc. For grade 2 GU symptoms, the threshold values were 23.6 cc for V EQD2-70 Gy and 38.1 cc for V EQD2-65 Gy. Conclusions Hypofractionated radiotherapy for prostate cancer is well tolerated and associated with manageable acute side effects. The absolute dose-volume parameters of rectum and bladder predict for acute toxicities.</description><identifier>ISSN: 0958-3947</identifier><identifier>EISSN: 1873-4022</identifier><identifier>DOI: 10.1016/j.meddos.2016.10.002</identifier><identifier>PMID: 28129973</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Acute toxicity ; BLADDER ; D QUARKS ; DISEASE INCIDENCE ; DOSE EQUIVALENTS ; Dose Hypofractionation ; HAZARDS ; Hematology, Oncology and Palliative Medicine ; Humans ; Hypofractionated radiation therapy ; Male ; NEOPLASMS ; PATIENTS ; PROCTITIS ; PROSTATE ; Prostatic Neoplasms - radiotherapy ; RADIATION DOSES ; RADIATION PROTECTION AND DOSIMETRY ; Radiology ; RADIOLOGY AND NUCLEAR MEDICINE ; RADIOTHERAPY ; Radiotherapy, Intensity-Modulated - adverse effects ; RECTUM ; Retrospective Studies ; SIDE EFFECTS ; SYMPTOMS ; TOXICITY</subject><ispartof>Medical dosimetry : official journal of the American Association of Medical Dosimetrists, 2017, Vol.42 (1), p.18-23</ispartof><rights>American Association of Medical Dosimetrists</rights><rights>2017 American Association of Medical Dosimetrists</rights><rights>Copyright © 2017 American Association of Medical Dosimetrists. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c445t-e30a359d629834a0527ba4ba4150a2f985c6722bd94ee53bf0dcd1c707f9ea483</citedby><cites>FETCH-LOGICAL-c445t-e30a359d629834a0527ba4ba4150a2f985c6722bd94ee53bf0dcd1c707f9ea483</cites><orcidid>0000-0002-5567-9204</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.meddos.2016.10.002$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3536,27903,27904,45974</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28129973$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://www.osti.gov/biblio/22685176$$D View this record in Osti.gov$$Hfree_for_read</backlink></links><search><creatorcontrib>Arunsingh, Moses, M.D</creatorcontrib><creatorcontrib>Mallick, Indranil, M.D., D.N.B</creatorcontrib><creatorcontrib>Prasath, Sriram, M.Sc</creatorcontrib><creatorcontrib>Arun, B., M.Sc</creatorcontrib><creatorcontrib>Sarkar, Sandip, M.D</creatorcontrib><creatorcontrib>Shrimali, Raj Kumar, F.R.C.R</creatorcontrib><creatorcontrib>Chatterjee, Sanjoy, F.R.C.R</creatorcontrib><creatorcontrib>Achari, Rimpa, M.D</creatorcontrib><title>Acute toxicity and its dosimetric correlates for high-risk prostate cancer treated with moderately hypofractionated radiotherapy</title><title>Medical dosimetry : official journal of the American Association of Medical Dosimetrists</title><addtitle>Med Dosim</addtitle><description>Abstract Aims To report the acute toxicity and the dosimetric correlates after moderately hypofractionated radiotherapy for localized prostate cancer. Methods A total of 101 patients with localized prostate cancer were treated with image-guided intensity-modulated radiation therapy. Patients were treated to 65 Gy/25 Fr/5 weeks ( n = 18), or 60 Gy/20 Fr/4 weeks ( n = 83). Most (82.2%) had high-risk or pelvic node-positive disease. Acute toxicity was assessed using Radiation Therapy Oncology Group (RTOG) acute morbidity scoring criteria. Dose thresholds for acute rectal and bladder toxicity were identified. Results The incidence of acute grade 2 GI toxicity was 20.8%, and grade 2 genitourinary (GU) toxicity was 6.9%. No Grade 3 to 4 toxicity occurred. Small bowel toxicity was uncommon (Gr 2 = 4%). The 2 Gy equivalent doses (EQD2) to the rectum and bladder (α/β = 3) calculated showed that the absolute doses were more consistent predictors of acute toxicities than the relative volumes. Those with grade 2 or more GI symptoms had significantly higher V EQD2-60 Gy (13.2 vs 9.9 cc, p = 0.007) and V EQD2-50 Gy (20.6 vs 15.4 cc, p = 0.005). Those with grade 2 or more GU symptoms had significantly higher V EQD2-70 Gy (30.4 vs 18.4 cc, p = 0.001) and V EQD2-65 Gy (44.0 vs 28.8 cc, p = 0.001). The optimal cutoff value for predicting grade 2 acute proctitis, for V EQD2-60 Gy was 9.7 cc and for V EQD2-50 Gy was 15.9 cc. For grade 2 GU symptoms, the threshold values were 23.6 cc for V EQD2-70 Gy and 38.1 cc for V EQD2-65 Gy. Conclusions Hypofractionated radiotherapy for prostate cancer is well tolerated and associated with manageable acute side effects. The absolute dose-volume parameters of rectum and bladder predict for acute toxicities.</description><subject>Acute toxicity</subject><subject>BLADDER</subject><subject>D QUARKS</subject><subject>DISEASE INCIDENCE</subject><subject>DOSE EQUIVALENTS</subject><subject>Dose Hypofractionation</subject><subject>HAZARDS</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Hypofractionated radiation therapy</subject><subject>Male</subject><subject>NEOPLASMS</subject><subject>PATIENTS</subject><subject>PROCTITIS</subject><subject>PROSTATE</subject><subject>Prostatic Neoplasms - radiotherapy</subject><subject>RADIATION DOSES</subject><subject>RADIATION PROTECTION AND DOSIMETRY</subject><subject>Radiology</subject><subject>RADIOLOGY AND NUCLEAR MEDICINE</subject><subject>RADIOTHERAPY</subject><subject>Radiotherapy, Intensity-Modulated - adverse effects</subject><subject>RECTUM</subject><subject>Retrospective Studies</subject><subject>SIDE EFFECTS</subject><subject>SYMPTOMS</subject><subject>TOXICITY</subject><issn>0958-3947</issn><issn>1873-4022</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkUuLFDEQx4Mo7rj6DUQCnnusPPqRi7AsqysseFDPIZNU25nt6TRJxrVvfnTTtnrwIgRCVf3r9StCXjLYM2DNm-P-hM6FtOfFKq49AH9EdqxrRSWB88dkB6ruKqFke0GepXQEgFqCeEoueMe4Uq3YkR9X9pyR5vDdW58XaiZHfU60FPYnzNFbakOMOJqMifYh0sF_Haro0z2dY0i5-Kk1k8VIc8RiOfrg80BPwWEs5rjQYZlDH43NPky_BNE4H_JQ4vPynDzpzZjwxe__knx5d_P5-ra6-_j-w_XVXWWlrHOFAoyolWu46oQ0UPP2YGR5rAbDe9XVtmk5PzglEWtx6MFZx2wLba_QyE5cktdb3TKz16ksi3awYZrQZs1509WsbYpKbipbdksRez1HfzJx0Qz0il0f9YZdr9hXb8Fe0l5tafP5UMJ_k_5wLoK3mwDLit88xnUCLNScj-sALvj_dfi3gB395K0Z73HBdAznOBV8munENehP6-nXy7NGAKimET8BEHGtng</recordid><startdate>2017</startdate><enddate>2017</enddate><creator>Arunsingh, Moses, M.D</creator><creator>Mallick, Indranil, M.D., D.N.B</creator><creator>Prasath, Sriram, M.Sc</creator><creator>Arun, B., M.Sc</creator><creator>Sarkar, Sandip, M.D</creator><creator>Shrimali, Raj Kumar, F.R.C.R</creator><creator>Chatterjee, Sanjoy, F.R.C.R</creator><creator>Achari, Rimpa, M.D</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>OTOTI</scope><orcidid>https://orcid.org/0000-0002-5567-9204</orcidid></search><sort><creationdate>2017</creationdate><title>Acute toxicity and its dosimetric correlates for high-risk prostate cancer treated with moderately hypofractionated radiotherapy</title><author>Arunsingh, Moses, M.D ; Mallick, Indranil, M.D., D.N.B ; Prasath, Sriram, M.Sc ; Arun, B., M.Sc ; Sarkar, Sandip, M.D ; Shrimali, Raj Kumar, F.R.C.R ; Chatterjee, Sanjoy, F.R.C.R ; Achari, Rimpa, M.D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c445t-e30a359d629834a0527ba4ba4150a2f985c6722bd94ee53bf0dcd1c707f9ea483</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Acute toxicity</topic><topic>BLADDER</topic><topic>D QUARKS</topic><topic>DISEASE INCIDENCE</topic><topic>DOSE EQUIVALENTS</topic><topic>Dose Hypofractionation</topic><topic>HAZARDS</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Hypofractionated radiation therapy</topic><topic>Male</topic><topic>NEOPLASMS</topic><topic>PATIENTS</topic><topic>PROCTITIS</topic><topic>PROSTATE</topic><topic>Prostatic Neoplasms - radiotherapy</topic><topic>RADIATION DOSES</topic><topic>RADIATION PROTECTION AND DOSIMETRY</topic><topic>Radiology</topic><topic>RADIOLOGY AND NUCLEAR MEDICINE</topic><topic>RADIOTHERAPY</topic><topic>Radiotherapy, Intensity-Modulated - adverse effects</topic><topic>RECTUM</topic><topic>Retrospective Studies</topic><topic>SIDE EFFECTS</topic><topic>SYMPTOMS</topic><topic>TOXICITY</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Arunsingh, Moses, M.D</creatorcontrib><creatorcontrib>Mallick, Indranil, M.D., D.N.B</creatorcontrib><creatorcontrib>Prasath, Sriram, M.Sc</creatorcontrib><creatorcontrib>Arun, B., M.Sc</creatorcontrib><creatorcontrib>Sarkar, Sandip, M.D</creatorcontrib><creatorcontrib>Shrimali, Raj Kumar, F.R.C.R</creatorcontrib><creatorcontrib>Chatterjee, Sanjoy, F.R.C.R</creatorcontrib><creatorcontrib>Achari, Rimpa, M.D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>OSTI.GOV</collection><jtitle>Medical dosimetry : official journal of the American Association of Medical Dosimetrists</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Arunsingh, Moses, M.D</au><au>Mallick, Indranil, M.D., D.N.B</au><au>Prasath, Sriram, M.Sc</au><au>Arun, B., M.Sc</au><au>Sarkar, Sandip, M.D</au><au>Shrimali, Raj Kumar, F.R.C.R</au><au>Chatterjee, Sanjoy, F.R.C.R</au><au>Achari, Rimpa, M.D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Acute toxicity and its dosimetric correlates for high-risk prostate cancer treated with moderately hypofractionated radiotherapy</atitle><jtitle>Medical dosimetry : official journal of the American Association of Medical Dosimetrists</jtitle><addtitle>Med Dosim</addtitle><date>2017</date><risdate>2017</risdate><volume>42</volume><issue>1</issue><spage>18</spage><epage>23</epage><pages>18-23</pages><issn>0958-3947</issn><eissn>1873-4022</eissn><abstract>Abstract Aims To report the acute toxicity and the dosimetric correlates after moderately hypofractionated radiotherapy for localized prostate cancer. Methods A total of 101 patients with localized prostate cancer were treated with image-guided intensity-modulated radiation therapy. Patients were treated to 65 Gy/25 Fr/5 weeks ( n = 18), or 60 Gy/20 Fr/4 weeks ( n = 83). Most (82.2%) had high-risk or pelvic node-positive disease. Acute toxicity was assessed using Radiation Therapy Oncology Group (RTOG) acute morbidity scoring criteria. Dose thresholds for acute rectal and bladder toxicity were identified. Results The incidence of acute grade 2 GI toxicity was 20.8%, and grade 2 genitourinary (GU) toxicity was 6.9%. No Grade 3 to 4 toxicity occurred. Small bowel toxicity was uncommon (Gr 2 = 4%). The 2 Gy equivalent doses (EQD2) to the rectum and bladder (α/β = 3) calculated showed that the absolute doses were more consistent predictors of acute toxicities than the relative volumes. Those with grade 2 or more GI symptoms had significantly higher V EQD2-60 Gy (13.2 vs 9.9 cc, p = 0.007) and V EQD2-50 Gy (20.6 vs 15.4 cc, p = 0.005). Those with grade 2 or more GU symptoms had significantly higher V EQD2-70 Gy (30.4 vs 18.4 cc, p = 0.001) and V EQD2-65 Gy (44.0 vs 28.8 cc, p = 0.001). The optimal cutoff value for predicting grade 2 acute proctitis, for V EQD2-60 Gy was 9.7 cc and for V EQD2-50 Gy was 15.9 cc. For grade 2 GU symptoms, the threshold values were 23.6 cc for V EQD2-70 Gy and 38.1 cc for V EQD2-65 Gy. Conclusions Hypofractionated radiotherapy for prostate cancer is well tolerated and associated with manageable acute side effects. The absolute dose-volume parameters of rectum and bladder predict for acute toxicities.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>28129973</pmid><doi>10.1016/j.meddos.2016.10.002</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-5567-9204</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0958-3947
ispartof Medical dosimetry : official journal of the American Association of Medical Dosimetrists, 2017, Vol.42 (1), p.18-23
issn 0958-3947
1873-4022
language eng
recordid cdi_osti_scitechconnect_22685176
source MEDLINE; Elsevier ScienceDirect Journals
subjects Acute toxicity
BLADDER
D QUARKS
DISEASE INCIDENCE
DOSE EQUIVALENTS
Dose Hypofractionation
HAZARDS
Hematology, Oncology and Palliative Medicine
Humans
Hypofractionated radiation therapy
Male
NEOPLASMS
PATIENTS
PROCTITIS
PROSTATE
Prostatic Neoplasms - radiotherapy
RADIATION DOSES
RADIATION PROTECTION AND DOSIMETRY
Radiology
RADIOLOGY AND NUCLEAR MEDICINE
RADIOTHERAPY
Radiotherapy, Intensity-Modulated - adverse effects
RECTUM
Retrospective Studies
SIDE EFFECTS
SYMPTOMS
TOXICITY
title Acute toxicity and its dosimetric correlates for high-risk prostate cancer treated with moderately hypofractionated radiotherapy
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T13%3A29%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_osti_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Acute%20toxicity%20and%20its%20dosimetric%20correlates%20for%20high-risk%20prostate%20cancer%20treated%20with%20moderately%20hypofractionated%20radiotherapy&rft.jtitle=Medical%20dosimetry%20:%20official%20journal%20of%20the%20American%20Association%20of%20Medical%20Dosimetrists&rft.au=Arunsingh,%20Moses,%20M.D&rft.date=2017&rft.volume=42&rft.issue=1&rft.spage=18&rft.epage=23&rft.pages=18-23&rft.issn=0958-3947&rft.eissn=1873-4022&rft_id=info:doi/10.1016/j.meddos.2016.10.002&rft_dat=%3Cpubmed_osti_%3E28129973%3C/pubmed_osti_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/28129973&rft_els_id=S0958394716300966&rfr_iscdi=true